EUCTR2008-007798-18-DE进行中（未招募）1 期
An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction. - NEOPECX
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Competent to comprehend, sign, and date an IEC-approved informed consent form, written informed consent.
- •- Of either gender and aged 18 years or more.
- •- Diagnosed with histologically confirmed adenocarcinoma of the stomach or the gastroesophageal junction of Type I/II/III according to the classification of Siewert et al, 1996 (see Appendix E).
- •- Stage uT/3 or 4 N0/+ and M0 (see Appendix F) disease evaluated by endoscopic ultrasound, spiral computed tomography of the chest, abdomen and pelvis and by laparoscopy in uT3/T4 tumors.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •- Haematologic function, as follows (within 7 days of randomisation):
- •- Leucocyte count = 4,000/mm3
- •- Platelet count =100,000/mm3.
- •- Haemoglobin =10 g/dl
- •- Renal function, as follows (within seven days of randomisation):
- •- Serum creatinine = 1.5x of upper limit of normal (ULN)
- •- Creatinine clearance > 60 ml/kg/min measured either by 24-h urine sampling or calculated by using the Cockgroft-Gault formula .
- •- Hepatic function, as follows (within seven days of randomisation):
- •- Aspartate aminotransferase (AST) =3 x ULN
- •- Alanine aminotransferase (ALT) =3 x ULN.
- •- Bilirubin = 1.5 x ULN.
- •- Metabolic function, as follows (within 7 days of randomisation):
- •- Magnesium = lower limit of normal.
- •- Calcium = lower limit of normal.
- •- Subject is deemed a good candidate for surgery.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 170
排除标准
- •- Any metastatic disease.
- •- Other malignant tumours less than five years old. Exceptions include basocellular carcinoma, in situ cancer of the cervix of the uterus, or any curatively-treated other malignancies without evidence of disease for more than five years.
- •- Malignant ascites or pleural effusion.
- •- Prior anti-EGFr antibody therapy (e.g. cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g. erlotinib).
- •- Prior chemotherapy, radiotherapy or antibody therapy for gastric cancer or cancer of the gastro-oesophageal junction.
- •- Concomitant therapy with sorivudine or analogue compounds.
- •- Known previous or ongoing abuse of narcotic drug, other medication or alcohol.
- •- Significant cardiovascular disease including New York Heart Association (NYHA) grade II or greater congestive heart failure, peripheral arterial occlusive disease stage II or greater, symptomatic coronary heart disease, insufficiently treated arterial hypertension, unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia.
- •- History or evidence upon physical examination of CNS disease unless adequately treated, seizure not controlled with standard medical therapy, or history of stroke.
- •- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan.
- •- Pre-existing polyneuropathy grade >1 according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE), except for loss of tendon reflex as the only symptom.
- •- Treatment for systemic infection within 14 days before initiating study treatment.
- •- Active inflammatory bowel disease, serious gastric ulceration or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day).
- •- Suspected or known dihydropyrimidine dehydrogenase deficiency (DPD).
- •- Thrombosis or severe bleeding within six months prior to entry into the study (except for bleeding of the tumour before its surgical resection), evidence of bleeding diathesis or coagulopathy, or current or recent (within 10 days prior to initiation of study treatment) use of full-dose oral or parenteral anticoagulants for therapeutic purposes.
- •- History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results.
- •- Known positive test for human immunodeficiency virus infection, hepatitis C virus or chronic active hepatitis B infection.
- •- Known allergy to the investigational product, to any of its excipients, to monoclonal antibodies, or to any of the components of the chemotherapy regimen.
- •- Any co-morbid disease that would increase risk of toxicity.
- •- Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures.
- •- Any investigational agent or participation in another clinical trial within 30 days prior to randomisation.
- •- Must not have had a major surgical procedure within 28 days of randomisation.
- •- Subject who is pregnant or breast feeding.
- •- Woman or man of childbearing potential not consenting to use adequate contraceptive precautions (intrauterine contraceptive device, contraceptive implants, injectables (hormonal depot), transdermal hormonal contraception (contraceptive patch), sexual abstinence or vasectomised partner) during the course of the study
研究者
相似试验
进行中（未招募）
1 期
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 DiseaseCoronavirus disease 2019 (COVID-19) / SARS-CoV-2 DiseaseMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: PTClassification code 10084460Term: COVID-19 treatmentSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084270Term: SARS-CoV-2 acute respiratory diseaseSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 23.1Level: LLTClassification code 10084439Term: SARS-CoV-2 serology test positiveSystem Organ Class: 100000004848MedDRA version: 21.1Level: LLTClassification code 10054540Term: Passive immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2020-001632-10-DERuprecht-Karls-Universität Heidelberg, Medical Faculty, University Hospital Heidelberg -174
尚未招募
2 期
Two drug therapy versus three drug therapy in resectable locally advanced oral cavity cancerCTRI/2024/07/071188AIIMS, New Delhi
进行中（未招募）
1 期
A Phase 2 Trial of BMS-986218 or BMS-986218/Nivolumab in Combination with Docetaxel in Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003990-74-GRBristol-Myers Squibb International Corporation204
尚未招募
3 期
Can a medicine help in curing viral infectioCTRI/2020/05/025068Christian Medical College Vellore
尚未招募
2 期
Comparison of two ways of using medications for preventing graft versus host disease after a half-matched stem cell transplantCTRI/2024/06/068451Indian Council of Medical Research